Cost-effectiveness analysis of artificial intelligence (AI) for response prediction of neoadjuvant radio(chemo)therapy in locally advanced rectal cancer (LARC) in the Netherlands
Expert Review of Pharmacoeconomics & Outcomes Research · 2026
DOI: 10.1080/14737167.2026.2615683 ↗Kurz gefasst
Fachartikel in der Zeitschrift Expert Review of Pharmacoeconomics & Outcomes Research, 2026. Verfasst von L Maas und 16 weiteren Autor:innen. Beteiligte Einrichtung: Business department, Radiomics. Bio, Liege, Belgium. Hauptthemen laut MEDLINE: Artificial Intelligence, Neoadjuvant Therapy, Rectal Neoplasms. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: European Union’s Horizon 2020 research and innovation program.
Abstract (Originalsprache)
BACKGROUND: Given the potential of artificial intelligence (AI) and the increasing importance of understanding AI's economic impact, this study aims to provide insights into the potential cost-effectiveness of an AI tool in the response prediction to neoadjuvant chemoradiotherapy (nCRT) of Stage II-III LARC patients in comparison to usual care (UC). METHODS: This study included a state-transition Markov model from a Dutch societal perspective. Quality-adjusted life years (QALY) and costs were simulated over a 10-year horizon. Sensitivity analyses and a threshold analysis were performed. Results were presented as incremental cost-effectiveness ratios. RESULTS: With incremental cost savings of -€2,530,000 per QALY gained per 1000 patients, the AI is dominant in the base-case. Main drivers of cost-effectiveness were the clinical complete response incidence and specificity of the tool. Cost-effectiveness was maintained at a cost of €1,100 and €2,100 for an AI performance of 0.85 and 0.90. DISCUSSION: Findings of this study present the economic impact of a hypothetical AI-based approach to treatment response prediction in Stage II-III LARC patients who receive nCRT and are eligible for consecutive surgery. The results of this study highlight the complexity of healthcare decision-making in tools that could be cost-saving yet yield lower effectiveness when parameters are uncertain.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Business department, Radiomics. Bio, Liege, Belgium.
- Department of Health Services Research, Care and Public Health Research Institute, Maastricht University, Maastricht, The Netherlands.
- Department of Imaging and Pathology, Biomedical MRI Unit, Leuven, Belgium.
- 2nd Division of Radiology, Medical University of Gdańsk, Gdansk, Poland.
- Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdansk, Poland.
- Digital Technology and Innovation, Siemens Healthineers, Erlangen, Germany.
ORCID-Profile: L Maas, C Contreras-Meca, S Ghezzo, F Belmans, A Corsi, J Cant, W Vos, M Bobowicz, M Rygusik, P T Wysocki, M E R Weiss, L Annemans, M Hiligsmann
Förderung
- European Union’s Horizon 2020 research and innovation program
Zitieren
APA
Maas, L., Contreras-Meca, C., Ghezzo, S., Belmans, F., Corsi, A., Cant, J., Vos, W., Bobowicz, M., Rygusik, M., Wysocki, P. T., Weiss, M. E. R., Neri, E., Caputo, F. P., Franceschello, R., Fanni, S. C., Annemans, L., & Hiligsmann, M. (2026). Cost-effectiveness analysis of artificial intelligence (AI) for response prediction of neoadjuvant radio(chemo)therapy in locally advanced rectal cancer (LARC) in the Netherlands. Expert Review of Pharmacoeconomics & Outcomes Research. https://doi.org/10.1080/14737167.2026.2615683
Vancouver
Maas L, Contreras-Meca C, Ghezzo S, Belmans F, Corsi A, Cant J, et al. Cost-effectiveness analysis of artificial intelligence (AI) for response prediction of neoadjuvant radio(chemo)therapy in locally advanced rectal cancer (LARC) in the Netherlands. Expert Review of Pharmacoeconomics & Outcomes Research. 2026. doi:10.1080/14737167.2026.2615683
BibTeX
@article{Maas2026,
author = {Maas, L and Contreras-Meca, C and Ghezzo, S and Belmans, F and Corsi, A and Cant, J and Vos, W and Bobowicz, M and Rygusik, M and Wysocki, P T and Weiss, M E R and Neri, E and Caputo, F P and Franceschello, R and Fanni, S C and Annemans, L and Hiligsmann, M},
title = {Cost-effectiveness analysis of artificial intelligence (AI) for response prediction of neoadjuvant radio(chemo)therapy in locally advanced rectal cancer (LARC) in the Netherlands},
journal = {Expert Review of Pharmacoeconomics & Outcomes Research},
year = {2026},
doi = {10.1080/14737167.2026.2615683}
}
EUVIMED